| Study | Reason for exclusion |
|---|---|
| Bark 1997 | Allocation: not randomised, review of three studies. Authors contacted for further information. |
| Barnes 1998 | Allocation: not randomised, a review. |
| Borison 1995 | Allocation: not randomised, a review. |
| Braus 1996 | Allocation: not randomised, before and after study. |
| Brown 1997 | Allocation: not randomised, case series. |
| Buchsbaum 1997 | Allocation: randomised. Participants: people with schizophrenia. N=16. Intervention: sertindole versus haloperidol. Outcomes: positron emission tomography scan study with no clinical outcomes. |
| Daniel 1995 | Allocation: not randomised, case series. |
| Dunn 1996 | Allocation: not randomised, review. |
| Geracioti 1998 | Allocation: not randomised, case history (participant from M93‐098 study). |
| Granneman 1997 | Allocation: not randomised, case series. |
| Hale 1998 | Allocation: not randomised, review. |
| Janicak 1996 | Allocation: not randomised, review. |
| Mack 1997 | Allocation: not randomised, review. |
| Moeller 1998 | Allocation: not randomised, review. |
| Pezawas 1997 | Allocation: not randomised, case series. |
| Potkin 1994 | Allocation: randomised (study M93‐098). Participants: people with schizophrenia (DSM‐III‐R, DSM‐IV). Interventions: sertindole 20mg/day (N=117) versus sertindole 24mg/day (N=114) versus haloperidol 16mg/day (N=115) versus placebo (N=116). Outcomes: No usable outcome data, due to 59% loss to follow up and no information given on either why participants did not complete the study or their groups of origin. |
| Rasmussen 1997 | Allocation: not randomised, review. |
| Sebree 1996 | Allocation: randomisation not mentioned, described as controlled. Participants: people with schizophrenia. N=16. Intervention: different dose intervals of sertindole (every day versus every other day). |
| Tamminga 1997 | Allocation: not randomised, review. |
| Wehnert 1997 | Allocation: not randomised, cohort study. |
| Wehnert 1997b | Allocation: not randomised, review of path analysis of two randomised trials (M93‐113 and M93‐098), no results presented. |
| Zimbroff 1997 | Allocation: randomised (study M93‐113). Participants: schizophrenia (DSM‐III‐R or DSM‐IV). N=497. Interventions: sertindole 12mg/day (n=76) versus sertindole 20mg/day (n=68) versus sertindole 24mg/day (n=72) versus haloperidol 4mg/day (n=71) versus haloperidol 8mg/day (n=67) versus haloperidol 16mg/day (n=70) versus placebo (n=73). Outcomes: no usable outcome data, due to 51% loss to follow up and insufficient information given on those who did not complete the study (the number of participants who discontinued treatment were not presented separately for each treatment group). |
DSM = Diagnostic and Statistical Manual of Mental Disorders.